Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY004 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT06005649Phase 2Withdrawn
- Sponsor
- Juventas Cell Therapy Ltd.
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
A Phase 2 trial of HY 004 in B-cell non-Hodgkin lymphoma, sponsored by Juventas Cell Therapy Ltd.. Planned start Sep 2025; status: withdrawn.
02
Drugs
HY 004
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06005649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005649.